Form 4: CURIS CMO Converts Preferred Stock to Common Shares

CURIS's Chief Medical Officer, Dr. Ahmed Hamdy, converted 50 shares of Series B Convertible Preferred Stock into 66,667 shares of common stock on March 20, 2026.

Summary

• Dr. Ahmed Hamdy, Chief Medical Officer (CMO) of CURIS INC, converted 50 shares of Series B Convertible Non-Redeemable Preferred Stock into 66,667 shares of Common Stock.
• The conversion occurred automatically at 5 p.m. Eastern Time on March 20, 2026, as per the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock.
• Each share of Series B Preferred Stock converted into 1,333.33 shares of Common Stock for no additional consideration.
• The Series B Preferred Stock was originally sold to Dr. Hamdy as part of a 'Security' package, which also included Series A, B, and C Warrants, at a purchase price of $1,000.00 per Security.
• Following this transaction, Dr. Hamdy directly beneficially owns 66,667 shares of CURIS INC Common Stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction, with a slight positive tilt due to a key executive increasing their direct common stock holdings, which aligns their interests with other shareholders.

Positives

• Increased direct common stock ownership by a key executive, Dr. Ahmed Hamdy, which aligns his interests more closely with common shareholders.
• The conversion occurred without additional consideration, indicating a pre-existing beneficial structure and a planned event.

Future Outlook

This Form 4 filing reports a historical insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider conversions of preferred stock to common stock are a routine part of capital structure management and executive compensation, often tied to pre-determined vesting schedules or conversion triggers. This specific conversion by a Chief Medical Officer could be seen as a positive signal of long-term commitment to the company's equity.

Comparison to Industry Standards

• The reporting of insider transactions via Form 4 is a standard regulatory requirement across all publicly traded U.S. companies, ensuring transparency in executive and director stock ownership changes.
• The conversion mechanism of preferred stock to common stock is a common feature in corporate finance, often used in executive compensation or financing rounds, and its specific terms are unique to CURIS INC's Certificate of Designations.

Related Party Transactions

• The reporting person, Dr. Ahmed Hamdy, acquired the Series B Convertible Preferred Stock (part of a 'Security' package including warrants) at a purchase price of $1,000.00 per Security, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Increased alignment of a key executive's interests with common shareholders, potentially signaling confidence in the company's future.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled conversion of preferred stock to common stock by a key executive. While it shows continued executive alignment, it does not provide new fundamental information to warrant a change in investment recommendation. Investors should hold and monitor broader company performance and strategic developments.

Keywords

CURIS INC, CRIS, Form 4, Insider Transaction, Stock Conversion, Preferred Stock, Common Stock, Ahmed Hamdy, CMO, Beneficial Ownership